Mucosal combination vaccines for bacterial meningitis

ABSTRACT

A composition for mucosal delivery, comprising two or more of the following: (a) an antigen which induces an immune response against  Haemophilus influenzae ; (b) an antigen which induces an immune response against  Neisseria meningitidis ; and (c) an antigen which induces an immune response against  Streptococcus pneumoniae . The combination allows a single dose for immunising against three separate causes of a common disease, namely bacterial meningitis.

All documents cited herein are hereby incorporated by reference in theirentirety.

FIELD OF THE INVENTION

This application relates to mucosal meningitis vaccines, especiallyintranasal vaccines.

BACKGROUND TO THE INVENTION

Meningitis is the inflammation of the tissues which cover the brain andspinal cord. It may have a bacterial cause or a viral cause, withbacterial meningitis generally being more serious.

The main pathogen responsible for bacterial meningitis is Neisseriameningitidis (meningococcus), but other relevant pathogens includeStreptococcus pneumoniae (pneumococcus), Haemophilus influenzae (Hib),and Streptococcus agalactiae (GBS). N. meningitidis also causesmeningococcal septicaemia, which is the main life-threatening aspect ofinfection.

Vaccines to protect against Hib infection have been available for manyyears. A vaccine that protects against serogroup C meningococcus(‘MenC’) was introduced in several European countries in 1999-2000. Apneumococcal vaccine entered into routine use in America in 2000.

The vaccines against these three pathogens are based on antigeniccapsular polysaccharides, with conjugation to carrier proteins beingused to enhance the polysaccharides' immunogenicity. These vaccines areadministered by injection, although investigations into mucosal deliveryhave been described for mice e.g. reference 1 describes the intranasaladministration of Hib conjugate vaccines and reference 2 describesintranasal administration of MenC conjugate vaccines. (see also ref. 3).Mucosal delivery of vaccines represents an attractive approach toovercome the problem of the high number of injections administered toyoung children. In addition, as most pathogens initially infect atmucosal surfaces, inducing mucosal immunity at the site of infectionwould likely contribute to optimal protective immunity.

Intranasal and oropharyngeal delivery of vesicle-based vaccines againstserogroups B meningococcus (‘MenB’) has also been described [e.g. ref4], as has the intranasal delivery of B. pertussis bacteria whichexpress N. meningitidis transferrin-binding protein B [5]. Reference 6describes the intranasal delivery of pneumococcal conjugate vaccines[see also refs. 7 & 8].

It is an object of the invention to provide improvements in the mucosaldelivery of meningitis vaccines.

DISCLOSURE OF THE INVENTION

The invention provides a composition for mucosal delivery, comprisingtwo or more of the following: (a) an antigen which induces an immuneresponse against Haemophilus influenzae; (b) an antigen which induces animmune response against Neisseria meningitidis; and (c) an antigen whichinduces an immune response against Streptococcus pneumoniae.

Combining different antigens reduces the number of different doses whichneed to be administered in order to immunise against multiple pathogens.This is typically seen as an advantage for injectable vaccines, wherethe number of painful injections is reduced, but it is less important inmucosal vaccines (e.g. intranasal vaccines) because of the lowerdiscomfort levels associated with delivery. However, combined antigencompositions are advantageous even for mucosal delivery because patientcompliance is improved and transport/storage of medicines isfacilitated.

Although combining antigens into a single dose is attractive [e.g. refs.9 to 12], it presents difficulties due to interactions between thevarious components once combined, particularly in liquid formulations[13]. Issues which arise include antigen interference, antigencompetition [14,15], antigen degradation, epitope suppression, andadjuvant compatibility. Quality control of mixtures is also moredifficult. Furthermore, existing knowledge on combining antigens focuseson injectable, not mucosal, vaccines.

Despite these difficulties, the inventors have surprisingly found thatantigens from Haemophilus influenzae, Neisseria meningitidis and/orStreptococcus pneumoniae can be combined for mucosal delivery withoutthe negative consequences which would haven been expected. Combiningantigens from these three organisms is also advantageous because itallows a single dose to deal with three separate causes of a commondisease, namely bacterial meningitis. Combined meningitis vaccines ofthis type have previously been reported [16], but mucosal administrationwas not reported.

Mucosal Delivery

The composition of the invention is for mucosal delivery.

Of the various mucosal delivery options available, the intranasal routeis the most practical as it offers easy access with relatively simpledevices that have already been mass produced. In addition, intranasalimmunisation appears to be more potent that alternative routes. Thus thepreferred route for mucosal delivery is the intranasal route, and thecomposition of the invention is preferably adapted for intranasaladministration, such as by nasal spray, nasal drops, gel or powder [e.g.refs 17 & 18].

Alternative routes for mucosal delivery of the vaccine are oral,intragastric, pulmonary, intestinal, rectal, ocular, and vaginal routes.

(a) Haemophilus influenzae Antigen

The H. influenzae antigen in the composition will typically be acapsular saccharide antigen. Saccharide antigens from H. influenzae bare well known.

Advantageously, the Hib saccharide is covalently conjugated to a carrierprotein, in order to enhance its immunogenicity, especially in children.The preparation of polysaccharide conjugates in general, and of the Hibcapsular polysaccharide in particular, is well documented [e.g.references 19 to 27 etc.]. The invention may use any suitable Hibconjugate.

The saccharide moiety of the conjugate may be a polysaccharide (e.g.full-length polyribosylribitol phosphate (PRP)), but it is preferred tohydrolyse polysaccharides (e.g. by acid hydrolysis) to formoligosaccharides (e.g. MW from ˜1 to ˜5 kDa). If hydrolysis isperformed, the hydrolysate may be sorted by size in order to removeoligosaccharides which are too short to be usefully immunogenic.Size-separated oligosaccharides are preferred saccharide antigens.

Preferred carrier proteins are bacterial toxins or toxoids, such asdiphtheria or tetanus toxoids. These are commonly used in conjugatevaccines. The CRM197 diphtheria toxoid is particularly preferred [28].Other suitable carrier proteins include the N. meningitidis outermembrane protein [29], synthetic peptides [30,31], heat shock proteins[32,33], pertussis proteins [34,35], protein D from H. influenzae [36],cytokines [37], lymphokines [37], hormones [37], growth factors [37],toxin A or B from C. difficile [38], iron-uptake proteins [39] etc. Itis possible to use mixtures of carrier proteins.

The saccharide moiety may be conjugated to the carrier protein directlyor via a linker. Direct linkage may be achieved by oxidation of thepolysaccharide followed by reductive amination with the protein, asdescribed in, for example, refs. 40 & 41. Linkage via a linker group maybe made using any known procedure, for example, the procedures describedin refs. 42 & 43. Suitable linkers include carbonyl, adipic acid,B-propionamido [44], nitrophenyl-ethylamine [45], haloacyl halides [46],glycosidic linkages [47], 6-aminocaproic acid [48], ADH [49], C₄ to C₁₂moieties [50] etc.

The saccharide will typically be activated or functionalised prior toconjugation. Activation may involve, for example, cyanylating reagentssuch as CDAP (e.g. 1-cyano-4-dimethylamino pyridinium tetrafluoroborate[51, 52]. Other suitable techniques use carbodiimides, hydrazides,active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide,S-NHS, EDC, TSTU; see also the introduction to reference 53). Reductiveamination is a preferred technique.

A preferred conjugate comprises the Hib saccharide covalently linked toCRM197 via adipic acid succinic diester [54, 55].

Compositions of the invention may comprise more than one Hib antigen.

(b) Neisseria meningitidis Antigen

The N. meningitidis antigen in the composition will typically be acapsular saccharide antigen (e.g. from serogroups A, C, W135 or Y).Saccharide antigens from N. meningitidis are well known. Where theantigen is from serogroup B, however, it is preferred that the antigenis a protein antigen. This is because the native capsular polysaccharideof MenB contains self-antigens. If a saccharide antigen is to be usedfrom serogroup B, it is preferred to use a modified saccharide antigen[e.g. refs. 56, 57, 58) e.g. one modified by N-propionylation. Chemicalmodification of saccharides from other serogroups is also possible.

The saccharide is preferably an oligosaccharide i.e. a fragment of acapsular polysaccharide. Polysaccharides may be manipulated to giveshorter oligosaccharides and these may be obtained by purificationand/or sizing of the native polysaccharide (e.g. by hydrolysis in mildacid, by heating, by sizing chromatography etc.). Preferred MenColigosaccharides are disclosed in references 59 & 60.

The saccharide is preferably conjugated to a carrier protein asdescribed above.

Compositions of the invention may comprise more than one meningococcalantigen. It may be preferred to include capsular saccharide antigensfrom at least two (i.e. 2, 3 or 4) of serogroups A, C, W135 and Y of N.meningitidis [61].

Where a mixture comprises capsular saccharides from both serogroups Aand C, it is preferred that the ratio (w/w) of MenA saccharide:MenCsaccharide is greater than 1 (e.g. 2:1, 3:1, 4:1, 5:1, 10:1 or higher).Surprisingly, improved immunogenicity of the MenA component has beenobserved when it is present in excess (mass/dose) to the MenC component[61].

Where a mixture comprises capsular saccharides from serogroup W135 andat least one of serogroups A, C and Y, it has surprisingly been foundthat the immunogenicity of the MenW135 saccharide is greater whenadministered in combination with the saccharide(s) from the otherserogroup(s) than when administered alone (at the same dosage etc.)[61]. Thus the capacity of the MenW135 antigen to elicit an immuneresponse is greater than the immune response elicited by an equivalentamount of the same antigen when delivered without association with theantigens from the other serogroups. Such enhanced immunogenicity can bedetermined by administering the MenW135 antigen to control animals andthe mixture to test animals and comparing antibody titres against thetwo using standard assays such as bactericidal titres, radioimmunoassayand ELISAs etc. Vaccines comprising synergistic combinations ofsaccharides from serogroup W135 and other serogroups are immunologicallyadvantageous as they allow enhanced anti-W135 responses and/or lowerW135 doses.

Where a protein antigen from serogroup B is used, it is preferred to useone of the proteins disclosed in references 62 to 71]. Preferred proteinantigens comprise the ‘287’ protein or derivatives (e.g. ΔG287).

It is also possible to use an outer membrane vesicle (OMV) antigen forserogroup B [e.g. 72, 73].

Compositions of the invention may comprise more than one meningococcalantigen.

(c) Streptococcus pneumoniae Antigen

The S. pneumoniae antigen in the composition will typically be acapsular saccharide antigen which is preferably conjugated to a carrierprotein as described above [e.g. 74, 75, 76].

It is preferred to include saccharides from more than one serotype of S.pneumoniae. For example, mixtures of polysaccharides from 23 differentserotype are widely used, as are conjugate vaccines with polysaccharidesfrom between 5 and II different serotypes [77]. For example, PrevNar™contains antigens from seven serotypes (4, 6B, 9V, 14, 18C, 19F, and23F) with each saccharide individually conjugated to CRM197 by reductiveamination.

Compositions of the invention may thus comprise more than onepneumococcal antigen.

Further Components—Adjuvants

Compositions of the invention will usually comprise a mucosal adjuvant.Mucosal adjuvants include, but are not limited to, (A) E. coliheat-labile enterotoxin (“LT”), or detoxified mutants thereof, such asthe K63 or R72 mutants [e.g. Chapter 5 of ref. 78]; (B) cholera toxin(“CT”), or detoxified mutants thereof [e.g. Chapter 5 of ref. 78]; or(C) microparticles (i.e. a particle of ˜100 nm to ˜150 μm in diameter,more preferably ˜200 nm to ˜30 μm in diameter, and most preferably ˜500nm to ˜10 μm in diameter) formed from materials that are biodegradableand non-toxic (e.g. a poly(α-hydroxy acid), a polyhydroxybutyric acid, apolyorthoester, a polyanhydride, a polycaprolactone etc.); (D) apolyoxyethylene ether or a polyoxyethylene ester [79]; (E) apolyoxyethylene sorbitan ester surfactant in combination with anoctoxynol [80] or a polyoxyethylene alkyl ether or ester surfactant incombination with at least one additional non-ionic surfactant such as anoctoxynol [81]; (F) chitosan [e.g. 82]; (G) an immunostimulatoryoligonucleotide (e.g. a CpG oligonucleotide), (H) double stranded RNA;(1) a saponin [83]; (J) monophosphoryl lipid A mimics, such asaminoalkyl glucosaminide phosphate derivatives e.g. RC-529 [84]; or (K)polyphosphazene (PCPP). Other mucosal adjuvants are also available [e.g.see chapter 7 of ref. 85].

Preferred mucosal adjuvants are bacterial ADP-ribosylating toxins ortheir mutants. For example, cholera toxin (CT) or E. coli heat labiletoxin (LT) are potent mucosal adjuvants, as are their detoxifiedcounterparts [86]. CT and LT are homologous and are typicallyinterchangeable.

Detoxification of the CT or LT may be by chemical or, preferably, bygenetic means. Suitable examples include LT having a lysine residue atamino acid 63 [‘LT-K63’—ref. 87], and LT having an arginine residue atamino acid 72 [‘LT-R72’—ref. 88]. Other suitable mutants include LT witha tyrosine at residue 63 [‘Y63’—ref. 89] and the various mutantsdisclosed in reference 90, namely D53, K97, K104 and S106, as well ascombinations thereof (e.g. LT with both a D53 and a K63 mutation).

The composition may comprise a bioadhesive [91,92] such as esterifiedhyaluronic acid microspheres [93] or, in preferred embodiments, amucoadhesive selected from the group consisting of cross-linkedderivatives of poly(acrylic acid), polyvinyl alcohol, polyvinylpyrollidone, polysaccharides and carboxymethylcellulose.

Compositions of the invention may comprise more than one mucosaladjuvant.

Further Components—Antigens

The combination of antigens from H. influenzae, N. meningitidis and S.pneumoniae is advantageous because they all cause bacterial meningitis.Antigens which induce immune responses against further organisms mayalso be included in compositions of the invention e.g.

-   -   antigens from Helicobacter pylori such as CagA [94 to 97], VacA        [98, 99], NAP [100, 101, 102], HopX [e.g. 103], HopY [e.g. 103]        and/or urease.    -   an antigen from hepatitis A virus, such as inactivated virus        [e.g. 104, 105].    -   an antigen from hepatitis B virus, such as the surface and/or        core antigens [e.g. 105, 106].    -   an antigen from hepatitis C virus [e.g. 107].    -   an antigen from Bordetella pertussis, such as pertussis        holotoxin (PT) and filamentous haemagglutinin (FHA) from B.        pertussis, optionally also in combination with pertactin and/or        agglutinogens 2 and 3 [e.g., refs. 108 and 109].    -   a diptheria antigen, such as diphtheria toxoid [e.g., chapter 3        of ref. 117] e.g. the CRM₁₉₇ mutant [e.g. 83].    -   a tetanus antigen, such as a tetanus toxoid [e.g., chapter 4 of        ref. 114].    -   an antigen from N. gonorrhoeae [e.g. 62 to 65].    -   an antigen from Chlamydia pneumoniae [e.g. 110, 111, 112, 113,        114, 115, 116].    -   an antigen from Chlamydia trachomatis [e.g. 117].    -   an antigen from Porphyromonas gingivalis [e.g. 1 18].    -   polio antigen(s) [e.g. 119, 120] such as IPV or OPV.    -   rabies antigen(s) [e.g. 121] such as lyophilised inactivated        virus [e.g. 122, RabAvert™].    -   measles, mumps and/or rubella antigens [e.g. chapters 9, 10 & 11        of ref. 123].    -   influenza antigen(s) [e.g. chapter 19 of ref. 123], such as the        haemagglutinin and/or neuramimidase surface proteins.    -   antigen(s) from a paramyxovirus such as respiratory syncytial        virus (RSV [124,125]) and/or parainfluenza virus (PIV3 [126]).    -   an antigen from Moraxella catarrhalis [e.g. 127].    -   an antigen from Streptococcus agalactiae (group B streptococcus)        [e.g. 128, 129].    -   an antigen from Streptococcus pyogenes (group A streptococcus)        [e.g. 129, 130, 131].    -   an antigen from Staphylococcus aureus [e.g. 132].        The composition may comprise one or more of these further        antigens.

Where a conjugate is present, the composition may also comprise freecarrier protein [133].

It is preferred that the composition does not include whole bacteria(whether intact or lysed).

Compositions of the invention may comprise proteins which mimicsaccharide antigens e.g. mimotopes [134] or anti-idiotype antibodies.These may replace individual saccharine components, or may supplementthem. As an example, the vaccine may comprise a peptide mimic of theMenC [135] or the MenA [136] capsular polysaccharide in place of thesaccharide itself.

Compositions of the invention may comprise nucleic acid for ‘geneticimmunisation’ [e.g. 137]. The nucleic acid will encode a proteincomponent of the composition and may replace individual proteincomponents (including those of the previous paragraph), or maysupplement them. As an example, the vaccine may comprise DNA thatencodes a tetanus toxin.

Further Components—Formulation

The composition of the invention preferably includes a pharmaceuticallyacceptable carrier.

‘Pharmaceutically acceptable carriers’ include any carrier that does notitself induce the production of antibodies harmful to the individualreceiving the composition. Suitable carriers are typically large, slowlymetabolised macromolecules such as proteins, polysaccharides, polylacticacids, polyglycolic acids, polymeric amino acids, amino acid copolymers,trehalose [138] lipid aggregates (such as oil droplets or liposomes),and inactive virus particles. Such carriers are well known to those ofordinary skill in the art. The vaccines may also contain diluents, suchas water, saline, glycerol, etc. Additionally, auxiliary substances,such as wetting or emulsifying agents, pH buffering substances, and thelike, may be present. The carrier will be compatible with mucosaladministration. A thorough discussion of pharmaceutically acceptableexcipients is available in Remington's Pharmaceutical Sciences.

The composition of the invention is preferably sterile.

The composition of the invention is preferably buffered.

The composition of the invention is preferably pyrogen-free.

The composition of the invention may be packaged with its components(a), (b) and/or (c) in admixture, or these components may remainseparate until they are to be administered to a patient, at which stagethey will be combined. Where separate, the individual components mayeach be in lyophilised form or in solution/suspension. Where mixed, thecomponents will all be in lyophilised form or all insolution/suspension. Lyophilised components will be re-suspended (e.g.in buffer) prior to administration to a patient. Components such asadjuvants may be present in the buffer or in the lyophilised material.

Immunogenic Compositions

The composition of the invention is preferably an immunogeniccomposition (e.g. a vaccine). Formulation of vaccines based onsaccharides or saccharide-protein conjugates is well known in the art.

Immunogenic compositions comprise immunologically effective amounts ofantigens, as well as any other of other specified components, as needed.By ‘immunologically effective amount’, it is meant that theadministration of that amount to an individual, either in a single doseor as part of a series, is effective for treatment or prevention. Thisamount varies depending upon the health and physical condition of theindividual to be treated, age, the taxonomic group of individual to betreated (e.g. non-human primate, primate, etc.), the capacity of theindividual's immune system to synthesise antibodies, the degree ofprotection desired, the formulation of the vaccine, the treatingdoctor's assessment of the medical situation, and other relevantfactors. It is expected that the amount will fall in a relatively broadrange that can be determined through routine trials.

Methods of Treatment

Once formulated, the compositions of the invention can be administereddirectly to a patient, which will generally be a human. The human ispreferably a child or a teenager. A further preferred class of patientis an adult woman, and particularly a woman of child-bearing age or apregnant woman. Compositions of the invention are particularly suitedfor passively immunising children via the maternal route.

Antigens in the composition induce immune responses against certainbacteria. These immune responses are preferably protective i.e. theyprotect the patient from later infection by the bacteria. Thus thecompositions of the invention are preferably used for prophylaxis (i.e.to prevent infection), although they may also be used for therapeuticpurposes (i.e. to treat disease after infection). The immune responsespreferably involve the production of bactericidal antibodies in thepatient.

The invention provides a method of raising an immune response in apatient, comprising administering to a patient a vaccine according tothe invention via a mucosal route (e.g. intranasally). The immuneresponse is preferably protective against bacterial meningitis and/orbacteremia caused by Haemophilus influenzae, Neisseria meningitidisand/or Streptococcus pneumoniae. The individual antigenic components ofthe compositions are preferably administered simultaneously and incombination. In other embodiments, however, they may be administeredseparately, either simultaneously or sequentially. When they areadministered separately, the components are preferably delivered to thesame mucosal surface.

The invention also provides a composition of the invention for use as amedicament.

The invention also provides the use of: (a) an antigen which induces animmune response against Haemophilus influenzae; (b) an antigen whichinduces an immune response against Neisseria meningitidis; and (c) anantigen which induces an immune response against Streptococcuspneumoniae, in the manufacture of a medicament for immunising a patient.

These methods and uses of the invention may involve a prime/boostregime. The methods and uses of the invention may be a priming dosewhich will be followed by a booster dose, where the booster dose may beby a mucosal or parenteral route. Similarly, the methods and uses of theinvention may raise a booster response in a patient that has alreadybeen immunologically primed, where the primer dose may have been by amucosal or parenteral route. Booster doses may comprise fewer antigensthan priming doses e.g. they may use a single antigen.

Dosage treatment at priming and/or boosting may be a single dose or amultiple dose schedule. Compositions of the invention may be presentedin unit dose form.

Manufacturing Methods

The invention provides a method for producing a composition of theinvention, comprising the steps of mixing two or more of the following:(a) an antigen which induces an immune response against Haemophilusinfluenzae; (b) an antigen which induces an immune response againstNeisseria meningitidis; and (c) an antigen which induces an immuneresponse against Streptococcus pneumoniae, and formulating the mixturefor mucosal delivery.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows geometric mean serum IgG antibody titres against MenC. Thelabel on the X axis shows the adjuvant which was used. The plainleft-hand column in each pair shows data obtained after administrationof the saccharide antigen on its own, whereas the shaded right-handcolumn shows data obtained after administration of combined saccharideantigens. FIG. 1A shows anti-MenC responses and FIG. 1B shows anti-Hibresponses. Error bars are standard deviations within one standard error.

FIG. 2 shows bactericidal antibody titres against MenC. As in FIG. 1,shaded data were obtained using combined saccharide antigens.

FIG. 3 shows anti-MenC IgA titres from nasal wash. As before, shadeddata were obtained using combined saccharide antigens.

MODES FOR CARRYING OUT THE INVENTION

Combined Hib/MenC Composition

Neisseria meningitidis serogroup C capsular oligosaccharide was producedby selective end-reducing group activation of sized oligosaccharide. Thesame method was used for Haemophilus influenzae type B. The saccharideswere conjugated to protein carrier CRM197 through a hydrocarbon spacer[139] (Chiron Siena, Italy). The conjugates were diluted inphosphate-buffered saline (PBS) and combined with (i) mutant E. coliheat-labile enterotoxin LTK63 or LTR72), (ii) aluminium hydroxide(Superfos Biosector a/s) or (iii) Cholera toxin (CT) from Sigma. Forcombined administration, these formulations were mixed prior to use.

Mucosal Administration of the Composition

Two identical administration studies were performed simultaneously.Groups of 10 female BALB/C mice 6-10 weeks old were immunisedintranasally with 10 μg of MenC or Hib alone, combined with CT (1 μg),or with the LT mutants (1 μg and 10 μg). For comparison, an additionalgroup of mice was immunised IM with 10 μg of MenC or Hib adsorbed toAlum. The compositions were prepared on the same day as immunisation andmice were immunised on Days 0, 21, and 35. 50 μl of the compositionswere injected into the thigh or instilled into alternate nostrils inunaneesthetised mice. Blood samples were taken on Day 49 along withterminal nasal wash samples (NW).

To evaluate if the immunogenicity of the conjugates was impaired whenthe two were mixed, a third study was performed concurrently in whichthe two vaccines were administered simultaneously to the same groups ofmice, at the same doses and regimen described above.

Immunological Responses to the Compositions

Antibody responses against the MenC conjugate were measured by ELISAusing a modified procedure as previously described [140]. Briefly, ELISAplates were coated with adipidic dihydrazide-derivatised MenC saccharideover night at 4° C. Specific antibodies were developed with goat antiMouse IgG-horseradish peroxidase conjugate. MenC IgG antibody titres forthe test samples and the internal control were expressed as thereciprocal of the serum dilution giving OD=1.0. Each serum sample wasassayed in duplicate, and the average value was used to calculate thegeometrical mean and the standard deviation within one standard error.The antibody responses against Hib PRP were determined similarly to theMenC ELISA, except that the plates were coated with BSA conjugated PRP(PRP-BSA). Titres were expressed as OD_(450nm) for serum diluted 1:50.

Nasal washes were assayed for IgA anti-MenC using a bioluminescent assay(BIA) [141]. Briefly, identical reagents and coating procedure tomeasure serum IgG against MenC was used. Then, a biotinylated Goatanti-Mouse IgA specific was added as a first antibody. Titres representthe logarithmic dilution values extrapolated from the log RLU data atthe cutoff value calculated at least two standard deviations above meanbackground.

Complement-mediated bactericidal activity against MenC bacteria wasmeasured in pooled serum samples as previously described [140]. Titreswere determined by calculating the serum dilution showing a 50%reduction in the number of CFU after 1 hour incubation.

FIG. 1A shows geometric mean serum IgG antibody titres against MenC,either alone (plain columns) or in combination with Hib antigen (shadedcolumns). The serum antibody responses elicited by both LT mutants weresignificantly higher than those obtained with the antigen alone. LTR72exhibited a higher adjuvanticity than LTK63 at lower doses. Mostnotably, the antibody responses induced by intranasal immunisation withboth LT mutants were comparable to those achieved with wild-type CT, orthose induced by intramuscular immunisation with alum-adjuvantedvaccine. Importantly, the addition of a second conjugated saccharideantigen did not adversely affect the antibody responses to eitherantigen.

FIG. 1B shows geometric mean serum IgG antibody titres against Hib PRPsaccharide. As for for MenC, antibody responses induced by either LTmutant were higher than those achieved with the antigen alone. Again,LTR72 showed a better adjuvanticity. Comparable titres were induced inmice immunised intranasally with LT mutants and by alum-adjuvantedvaccine by intramuscular immunisation. In addition, there was noevidence of competition following combined intranasal immunisation withthe two saccharide conjugate vaccines, with responses induced againstHib when in combination with MenC being comparable to the responsesinduced by immunisation with Hib alone.

The levels of bactericidal antibodies induced by intranasal immunisationwith LT mutants closely correlate with the ELISA serum IgG responses,and were again comparable to the responses induced by CT, orintramuscular immunisation with alum adsorbed vaccine (FIG. 2)

Samples obtained from nasal wash following intranasal immunisation withMenC with either LT mutant showed higher IgA titers than those obtainedby intranasal immunisation in the absence of adjuvants (FIG. 3). Asexpected, intramuscular immunisation elicited very low IgA titers.

CONCLUSION

Potent serum antibody responses against N. meningitidis and H.influenzae can be induced by intranasal immunisation with conjugatevaccines in combination with mucosal adjuvants. Moreover, for the MenCantigen, the antibodies induced by intranasal immunisation had potentbactericidal activity, which is known to correlate with protectiveimmunity [142]. In addition, IgA responses in the nasal cavity wereinduced only in animals immunised through the intranasal route. Inducingsecretory immunity is important because the upper respiratory tract isthe portal of entry for several pathogens, including N. meningitidis andH. influenzae.

Based on antibody titres obtained with conjugate vaccines given aloneand in combination, and on the bactericidal activity measured againstMenC, the combination of two vaccines co-administered with mucosaladjuvant did not negatively influence the antibody responses againstMenC or Hib. The results thus suggest that intranasal immunisation is aneffective route of immunisation for polysaccharide-protein conjugatevaccines in combination with mucosal adjuvants such as LT mutants.

The same dose of LT mutants was sufficient to significantly enhance theimmunogenicity of both conjugate vaccines administered simultaneously.This is particularly important as it would reduce the amount of adjuvantneeded and the risks associated with potential toxicity. Importantly,pre-existing immunity against the LTK63 mutant does not affect theability of the mutant to act as an adjuvant for a second antigen [2].Furthermore, the potency of mucosally-delivered vaccines may be furtherimproved by formulating the vaccines in bioadhesive delivery systems[91].

In conclusion, combining polysaccharide-protein conjugate vaccines withLT mutants for intranasal immunisation is an effective approach tomucosal immunisation for pediatric use.

It will be understood that the invention is described above by way ofexample only and modifications may be made whilst remaining within thescope and spirit of the invention.

REFERENCES (the Contents of which are Hereby Incorporated in Full)

-   [1] Bergquist et al. (1998) APMIS 106:800-806.-   [2] Ugozzoli et al. (2001) J. Infect. Dis. 183:351-354.-   [3] Wenzel et al. (1973) J. Infect Dis, 128:3140.-   [4] Katial et al. (2002) Infect. Immun. 70:702-707.-   [5] Coppens et al. (2001) Infect. Immun. 69:5440-5446.-   [6] International patent application WO00/53221.-   [7] Yamamoto et al. (1998) J. Immunol. 161:4115-4121.-   [8] Wu et al. (1997) J. Infect. Dis. 175:839-   [9] Corbel (1994) Biologicals 22:353-360.-   [10] Rappuoli et al. European Commission COST/STD Initiative, Report    of Expert Panel VIII-   [11] Pichichero (2000) Pediatr Clin North Am 47:407-426.-   [12] International patent application WO02/00249.-   [13] Corbel (1994) Dev. Biol. Stand. 87:113-124.-   [14] Eskola et al. (1995) “Hib antibody responses after two doses of    combined DTPa-Hib conjugate vaccine as compared to separate    injections” in Abstract Book of the 35th Interscience Conference on    Antimicrobial Agents and Chemotherapy, San Francisco, 17-20    September 1995.-   [15] Schmitt et al. (2001) Pediatr Infect Dis J 20:767-774.-   [16] U.S. Pat. No. 6,251,401.-   [17] Almeida & Alpar (1996) J. Drug Targeting 3:455-467.-   [18] Agarwal & Mishra (1999) Indian J Exp Biol 37:6-16.-   [19] Lindberg (1999) Vaccine 17 Suppl 2:S28-36.-   [20] Buttery & Moxon (2000) J R Coll Physicians Lond 34:163-168.-   [21] Ahmad & Chapnick (1999) Infect Dis Clin North Am 13:113-33,    vii.-   [22] Goldblatt (1998) J. Med. Microbiol. 47:563-567.-   [23] European patent 0 477 508.-   [24] U.S. Pat. No. 5,306,492.-   [25] WO98/42721.-   [26] Dick et al. in Conjugate Vaccines (eds. Cruse et al.) Karger,    Basel, 1989, 10:48-114.-   [27] Hermanson Bioconjugate Techniques, Academic Press, San Diego    Calif. (1996).-   [28] Research Disclosure, 453077 (January 2002)-   [29] EP-A-0372501-   [30] EP-A-0378881-   [31] EP-A-0427347-   [32] WO93/17712-   [33] WO94/03208-   [34] WO98/58668-   [35] EP-A-0471177-   [36] WO00/56360-   [37] WO91/01146-   [38] WO00/61761-   [39] WO01/72337-   [40] U.S. Pat. No. 4,761,283-   [41] U.S. Pat. No. 4,356,170-   [42] U.S. Pat. No. 4,882,317-   [43] U.S. Pat. No. 4,695,624-   [44] WO00/10599-   [45] Gever et al., Med. Microbiol. Immunol, 165: 171-288 (1979).-   [46] U.S. Pat. No. 4,057,685.-   [47] U.S. Pat. Nos. 4,673,574; 4,761,283; 4,808,700.-   [48] U.S. Pat. No. 4,459,286.-   [49] U.S. Pat. No. 4,965,338-   [50] U.S. Pat. No. 4,663,160.-   [51] Lees et al. (1996) Vaccine 14:190-198.-   [52] WO95/08348.-   [53] International patent application WO98/42721.-   [54] Kanra et al. (1999) The Turkish Journal ofpaediatrics    42:421-427.-   [55] Ravenscroft et al. (2000) Dev Biol (Basel) 103: 35-47.-   [56] U.S. Pat. No. 4,727,136.-   [57] U.S. Pat. No. 5,811,102.-   [58] Jennings (1988) Adv Exp Med Biol 228:495-550.-   [59] Costantino etal. (1992) Vaccine 10:691-698.-   [60] Costantino et al. (1999) Vaccine 17:1251-1263/-   [61] UK patent application 0115176.0.-   [62] WO99/24578-   [63] WO99/36544-   [64] WO99/57280-   [651]WO00/22430-   [66] Tettelin et al. (2000) Science 287:1809-1815-   [67] Pizza et al. (2000) Science 287:1816-1820-   [68] WO00/66741-   [69] WO00/71725-   [70] WO01/64922-   [71] WO01/64920-   [72] WO01/52885-   [73] Bakke et al. (2001) Infect Immun 69(8):5010-5015.-   [74] Watson (2000) Pediatr Infect Dis J 19:331-332.-   [75] Rubin (2000) Pediatr Clin North Am 47:269-285, v.-   [76] Jedrzejas (2001) Microbiol Mol Biol Rev 65:187-207.-   [77] Zielen et al. (2000) Infect. Immun. 68:1435-1440.-   [78] Del Giudice et al. (1998) Molecular Aspects of Medicine, vol.    19, number 1.-   [79] International patent application WO99/52549.-   [80] International patent application WO01/21207.-   [81] International patent application WO01/21152.-   [82] International patent application WO99/27960.-   [83] International patent application WO00/62800.-   [84] Johnson et al. (1999) Bioorg Med Chem Lett 9:2273-2278.-   [85] Vaccine design: the subunit and adjuvant approach, eds. Powell    & Newman, Plenum Press 1995 (ISBN 0-306-44867-X.-   [86] Del Guidice et al. (1998) Molecular Aspects of Medicine    19:1-70.-   [87] WO93/13202-   [88] WO98/18298-   [89] Park et al. (2000) Exp. Mol. Med. 32:72-8.-   [90] Fontana et al. (1995) Infect. Immun. 63:2356-2360.-   [91] International patent application WO00/50078.-   [92] International patent application WO99/62546.-   [93] Singh et al. (2001) J. Cont. Rele. 70:267-276.-   [94] Covacci & Rappuoli (2000) J. Exp. Med. 19:587-592.-   [95] WO93/18150.-   [96] Covacci et al. (1993) Proc. Natl. Acad. Sci. USA 90: 5791-5795.-   [97] Tummuru et al. (1994) Infect. Immun. 61:1799-1809.-   [98] Marchetti et al. (1998) Vaccine 16:33-37.-   [99] Telford et al. (1994) J. Exp. Med. 179:1653-1658.-   [100] Evans et al. (1995) Gene 153:123-127.-   [101] WO96/01272 & WO96/01273, especially SEQ ID NO:6.-   [102] WO97/25429.-   [103] WO98/04702.-   [104] Bell (2000) Pediatr Infect Dis J 19:1187-1188.-   [105] Iwarson (1995) APMIS 103:321-326.-   [106] Gerlich et al. (1990) Vaccine 8 Suppl:S63-68 & 79-80.-   [107] Hsu et al. (1999) Clin Liver Dis 3:901-915.-   [108] Gustafsson et al. (1996) N. Engl. J. Med 334:349-355.-   [109] Rappuoli et al. (1991) TIBTECH 9:232-238.-   [110] WO02/02606.-   [111] Kalman et al. (1999) Nature Genetics 21:385-389.-   [112] Read et al. (2000) Nucleic Acids Res 28:1397-406.-   [113] Shirai et al. (2000) J. Infect. Dis. 181(Suppl 3):S524-S527.-   [114] International patent application WO99/27105.-   [115] International patent application WO00/27994.-   [116] International patent application WO00/37494.-   [117] International patent application WO99/28475.-   [118] Ross et al. (2001) Vaccine 19:4135-4142.-   [119] Sutter et al. (2000) Pediatr Clin North Am 47:287-308.-   [120] Zimmerman & Spann (1999) Am Fam Physician 59:113-118, 125-126.-   [121] Dreesen (1997) Vaccine 15 Suppl:S2-6.-   [122] MMWR Morb Mortal Wkly Rep 1998 Jan. 16; 47(1):12, 19.-   [123] Vaccines (1988) eds. Plotkin & Mortimer. ISBN 0-7216-1946-0.-   [124] Anderson (2000) Vaccine 19 Suppl 1:S59-65.-   [125] Kahn (2000) Curr Opin Pediatr 12:257-252.-   [126] Crowe (1995) Vaccine 13:415-421.-   [127] McMichael (2000) Vaccine 19 Suppl 1:S101-107.-   [128] Schuchat (1999) Lancet 353(9146):51-6.-   [129] International patent application PCT/GB01/04789.-   [130] Dale (1999) Infect Dis Clin North Am 13:227-43, viii.-   [131] Ferretti et al. (2001) PNAS USA 98: 4658-4663.-   [132] Kuroda et al. (2001) Lancet 357(9264):1225-1240; see also    pages 1218-1219.-   [133] WO96/40242-   [134] Charalambous & Feavers (2001) J Med Microbiol 50:937-939.-   [135] Westerink (2001) Int Rev Immunol 20:251-261.-   [136] Grothaus et al. (2000) Vaccine 18:1253-1263.-   [137] Donnelly et al. (1997) Annu Rev Immunol 15:617-648.-   [138] WO00/56365-   [139] Constatino et al. (1992) Vaccine 10:691-698.-   [140] Dan et al. (1998) Clin. Diagn. Lab. Immunol. 5:479-485.-   [141] Ugozzoli et al. (1998) Immunology 93:563-571.-   [142] Goldschneider et al. (1969) J Exp Med 129:1367-1384.

1. A composition for mucosal delivery, comprising two or more of thefollowing: (a) an antigen which induces an immune response againstHaemophilus influenzae; (O) an antigen which induces an immune responseagainst Neisseria meningitidis; and (c) an antigen which induces animmune response against Streptococcus pneumoniae.
 2. The composition ofclaim 1, adapted for intranasal administration.
 3. The composition ofclaim 2, in the form of a nasal spray, nasal drops, a gel or a powder.4. The composition of claim 1, wherein the H. influenzae antigen is acapsular saccharide antigen, conjugated to a carrier protein.
 5. Thecomposition of claim 4, wherein the saccharide antigen is anoligosaccharide.
 6. The composition of any preceding claim, wherein theN. meningitidis antigen is a capsular saccharide antigen from serogroupA, C, W135, or Y, conjugated to a carrier protein.
 7. The composition ofclaim 6, wherein the saccharide antigen is an oligosaccharide.
 8. Thecomposition of any one of claims 1-5, comprising N. meningitidisantigens from at least two of serogroups A, C, W135 and Y.
 9. Thecomposition of any one of claims 1, wherein the S. pneumoniae antigen isa capsular saccharide antigen, conjugated to a carrier protein.
 10. Thecomposition of claim 4, wherein the carrier protein is a diphtheria ortetanus toxoid.
 11. The composition of claim 10, wherein the carrierprotein is CRM197.
 12. The composition of any one of claims 1-5, whereineach of the H. influenzae antigen, the N. meningitidis antigen and theS. pneumoniae antigen is an oligosaccharide fragment of the capsularpolysaccharide, conjugated to a carrier protein.
 13. The composition ofclaim 12, wherein the H. influenzae antigen is conjugated to a firstcarrier protein, the N. meningitidis antigen is conjugated to a secondcarrier protein and the S. pneumoniae antigen is conjugated to a thirdcarrier protein.
 14. The composition of claim 12, wherein the H.influenzae antigen, the N. meningitidis antigen and the S. pneumoniaeantigen are conjugated to the same carrier protein.
 15. The compositionof claim 13, wherein the first, second and third carrier proteins areeach separately CRM197.
 16. The composition of any one of claims 1-5, 10or 11, further comprising a mucosal adjuvant.
 17. The composition ofclaim 16, wherein the mucosal adjuvant is a detoxified mutant of abacterial ADP-ribosylating toxin.
 18. The composition of claim 17,wherein the mucosal adjuvant is LT-K63 or LT-R72.
 19. A method ofraising an immune response in a patient, comprising administering to apatient the composition of any one of claims 1 to 5, 10 or
 11. 20. Thecomposition of any one of claims 1 to 5, 10 or 11, for use as amedicament.
 21. A method for immunising a patient comprising: providinga medicament, the medicament comprising (a) an antigen which induces animmune response against Haemophilus influenzae; (O) an antigen whichinduces an immune response against Neisseria meningitidis; and (c) anantigen which induces an immune response against Streptococcuspneumonia; immunising the patient with said medicament.
 22. A processfor producing the composition of any one of claims 1 to 5, 10 or 11,comprising the steps of: (i) mixing (a) an antigen which induces animmune response against Haemophilus influenzae, (O) an antigen whichinduces an immune response against Neisseria meningitidis, and (c) anantigen which induces an immune response against Streptococcuspneumoniae; and (ii) formulating the mixture for mucosal delivery.